Prevention and treatment of mucocutaneous adverse reactions associated with epidermal growth factor receptor inhibitors / 中华预防医学杂志
Chinese Journal of Preventive Medicine
;
(12): 87-94, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-935254
ABSTRACT
The epidermal growth factor receptor (EGFR) signaling is aberrantly overexpressed in many solid malignancies, making it an important target for anti-cancer biologic agents. Among them, epidermal growth factor receptor inhibitors (EGFRIs), which have been widely used in clinical practice, include anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors. A proportion of patients treated with EGFRIs develop specific, dose-dependent skin toxicity such as papulopustular rash, paronychia, xerosis and itch. These side effects can cause physical and psychosocial discomfort that may result in dose reduction, discontinuance, or replacement of the current EGFRIs treatment. Correct diagnosis and treatment of these skin and mucosal adverse effects associated with EGFRIs is of great significance for the tertiary prevention of malignant tumors. A review on EGFRI-related mucocutaneous adverse reactions is presented here, focusing on the pathogenesis, the various clinical manifestations, the strategies for prevention and treatment of these conditions.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Inhibidores de Proteínas Quinasas
/
Receptores ErbB
/
Anticuerpos Monoclonales
/
Neoplasias
/
Antineoplásicos
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Preventive Medicine
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS